Cempra (CEMP) : Mondays money flow data in Cempra (CEMP) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $3.1 million, whereas, $1.56 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.99, in favor of the bulls. The total money flow into the stock was $1.54 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $1.35 million. The total value of block trades done on upticks was $1.81 million. The value of bearish trades on downticks was only $0.45 million.The up/down ratio in the block trades was a healthy 3.97 in favor of the bulls, suggesting strong buying in the stock by large traders. Cempra (CEMP) fell $0.3 and traded at $18.17, down -1.62% for the day, over previous days close. On a weekly basis, the shares are 1.06% over the previous weeks close.
Cempra, Inc. has dropped 3.35% during the last 3-month period . Year-to-Date the stock performance stands at -41.7%. Shares of Cempra, Inc. appreciated by 0.5% during the last five trading days but lost 2.1% on a 4-week basis. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Commercial Officer) of Cempra, Inc., Moore David, had purchased 500 shares in a transaction dated on March 1, 2016. The transaction was executed at $16.18 per share with total amount equaling $8,090.
Cempra (NASDAQ:CEMP): On Mondays trading session , Opening price of the stock was $18.56 with an intraday high of $18.657. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $17.92. However, the stock managed to close at $18.15, a loss of 1.73% for the day. On the previous day, the stock had closed at $18.47. The total traded volume of the day was 479,055 shares.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.